Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 12;2012(9):CD002799.
doi: 10.1002/14651858.CD002799.pub2.

Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B

Rajeswari Aghoram  1 , Pin Cai, James A Dickinson
Affiliations
Review

Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B

Rajeswari Aghoram et al. Cochrane Database Syst Rev. .

Abstract

Background: Chronic hepatitis B virus infection is a risk factor for development of hepatocellular carcinoma. Alpha-foetoprotein and liver ultrasonography are used to screen patients with chronic hepatitis B for hepatocellular carcinoma. It is uncertain whether screening is worthwhile.

Objectives: To determine the beneficial and harmful effects of alpha-foetoprotein or ultrasound, or both, for screening of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Search methods: Electronic searches were performed until December 2011 in the Cochrane Hepato-Biliary Group Controlled Trials Register (December 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 4) in The Cochrane Library, MEDLINE (1948 to 2011), EMBASE (1980 to 2011), Science Citation Index Expanded (1900 to 2011), Chinese Medical Literature Electronic Database (WanFang Data 1998 to 2011), and Chinese Knowledge Resource Integrated Database (1994 to 2011).

Selection criteria: All published reports of randomised trials on screening for liver cancer were eligible for inclusion, irrespective of language of publication. Studies were excluded when the hepatitis B status was uncertain, the screening tests were not sensitive or widely-used, or when the test was used for diagnosis of hepatocellular carcinoma rather than screening.

Data collection and analysis: We independently analysed all the trials considered for inclusion. We wrote to the authors of one of the trials to obtain further information.

Main results: Three randomised clinical trials were included in this review. All of them had a high risk of bias. One trial was conducted in Shanghai, China. There are several published reports on this trial, in which data were presented differently. According to the 2004 trial report, participants were randomised to screening every six months with alpha-foetoprotein and ultrasonography (n = 9373) versus no screening (n = 9443). We could not draw any definite conclusions from it. A second trial was conducted in Toronto, Canada. In this trial, there were 1069 participants with chronic hepatitis B. The trial compared screening every six months with alpha-foetoprotein alone (n = 532) versus alpha-foetoprotein and ultrasound (n = 538) over a period of five years. This trial was designed as a pilot trial; the small number of participants and the rare events did not allow an effective comparison between the two modes of screening that were studied. The remaining trial, conducted in Taiwan and published as an abstract, was designed as a cluster randomised trial to determine the optimal interval for screening using alpha foetoprotein and ultrasound. Screening intervals of four months and 12 months were compared in the two groups. Further details about the screening strategy were not available. The trial reported on cumulative four-year survival, cumulative three-year incidence of hepatocellular carcinoma, and mean tumour size. The cumulative four-year survival was not significantly different between the two screening intervals. The incidence of hepatocellular cancer was higher in the four-monthly screening group. The included trials did not report on adverse events. It appears that the sensitivity and specificity of the screening modes were poor, accounting for a substantial number of false-positive and false-negative screening results.

Authors' conclusions: There is not enough evidence to support or refute the value of alpha-foetoprotein or ultrasound screening, or both, of hepatitis B surface antigen (HBsAg) positive patients for hepatocellular carcinoma. More and better designed randomised trials are required to compare screening against no screening.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Sherman 1995 {published data only}
    1. Sherman M, Peltekian M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432‐8. - PubMed
Wang 2011 {published data only}
    1. Wang JH, Chang KC, Hung CH, Chen CH, Lu SN. Hepatocellular carcinoma surveillance with 4 versus 12 months interval for patients with chronic viral hepatitis ‐ a randomized community study. Hepatology 2011;54(Suppl 1):1378A.
Zhang 2004 {published data only}
    1. Yang B, Zhang B, Tang Z. Randomized controlled prospective study of secondary prevention for primary liver cancer. Zhonghua Yi Xue Za Zhi 1999;79(12):887‐9. - PubMed
    1. Yang B, Zhang B, Tang Z. Screening and early diagnosis of primary liver cancer. Chinese Journal of Hepatology 1999;7(3):130‐2. - PubMed
    1. Yang B, Zhang B, Xu Y. A prospective study of early detection for primary liver cancer. Zhanghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 1996;18(6):442‐4. - PubMed
    1. Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, et al. Prospective study of early detection for primary liver cancer. Journal of Cancer Research and Clinical Oncology 1997;123:357‐60. - PubMed
    1. Zhang B, Yang B. Combined alpha‐fetoprotein and ultrasound as a screening test for primary liver cancer. Journal of Medical Screening 1999;6:108‐10. - PubMed

References to studies excluded from this review

Chen 2003 {published data only}
    1. Chen GJ. Study of screening for primary liver cancer in high risk population of an endemic area. Ahonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 1991;25(6):325‐8. - PubMed
    1. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised trial in Qidong, China. Journal of Medical Screening 2003;10:204‐9. - PubMed

Additional references

Black 2002
    1. Black WC, Haggstrom DA, Welch HG. All‐cause mortality in randomized trials of cancer screening. Journal of the National Cancer Institute 2002;94:167‐73. - PubMed
Bosch 2004
    1. Bosch XF, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127(Suppl):S5‐S16. - PubMed
Bruix 2010
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010;42(5):1208‐36. - PubMed
Burak 2010
    1. Burak KW, Kneteman NM. An evidence based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Albertal HCC algorithm. Canadian Journal of Gastroenterology 2010;24(11):643‐51. - PMC - PubMed
Chalasani 1999
    1. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Gastroenterology 1999;94(8):2224‐30. - PubMed
Chu 2000
    1. Chu CM. Natural history of chronic hepatitis B infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2000;15(Suppl):E25‐E30. - PubMed
Coon 2007
    1. Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technology Assessment 2007;11(34):1‐206. - PubMed
Croswel 2010
    1. Croswel JM, Ransohoff DF, Kramer BS. Principles of cancer screening: Lessons from history and study design issues. Seminars in Oncology 2010;37(3):202‐15. - PMC - PubMed
Farinati 2001
    1. Farinati F, Gianni S, Franco M. Hepatocellular carcinoma prevention and early diagnosis: where do we stand?. Acta Endoscopica 2001;31(4):515‐21.
Forner 2008
    1. Forner A, Vilana R, Ayuso C, Bilanchi L, Sole M, Ayuso JR, et al. Diagnosis of nodules 20mm or smaller in cirrhosis: prospective validation of the non‐invasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97‐104. - PubMed
Forner 2012
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245‐55. - PubMed
Gluud 2012
    1. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als‐Nielsen B, Colli A, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2012, Issue 6. Art. No.: LIVER.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997.
Iloeje 2007
    1. Iloeje UC, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clinical Gastroenterology and Hepatology 2007;5:921‐31. - PubMed
Jelic 2010
    1. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Annals of Oncology 2010;21(5 Suppl):V59‐V64. - PubMed
Keus 2010
    1. Keus F, Wetterslev J, Gluud C, Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology 2010;10:90. - PMC - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomised trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Kramer 2009
    1. Kramer BS, Croswel JM. Cancer screening: The clash of science and intuition. Annual Review of Medicine 2009;60:125‐37. - PubMed
Kudo 2010
    1. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. Journal of Gastroenterology and Hepatology 2010;25:439‐52. - PubMed
Kumagi 2009
    1. Kumagi T, Hiyasi Y, Hirschfield GM. Hepatocellular carcinoma for the non‐specialist. BMJ (Clinical Research Ed.) 2009;339:B5039‐B5044. - PubMed
Kunz 2007
    1. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.MR000012.pub2] - DOI - PubMed
Llovet 2003
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;363:1907‐17. - PubMed
Llovet 2008
    1. Llovet JM, Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 2008;100:698‐711. - PubMed
McMahon 2000
    1. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16 year population based study. Hepatology 2000;32(4):842‐7. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The prisma statement. BMJ (Clinical Research Ed.) 2009;339:B2535. - PMC - PubMed
O'Connor 2011
    1. O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Oliveri 2011
    1. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2] - DOI - PubMed
Pungpapong 2007
    1. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B infections: an update for clinicians. Mayo Clinic Proceedings 2007;82(8):967‐75. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed
Santi 2010
    1. Santi V, Trevisani F, Gramenzi A, Grinaschi A, Mirici‐Cappa F, Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. Journal of Hepatology 2010;53:291‐7. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Thomas 2010
    1. Thomas DL, Bisceglie AM, Alter HJ, Terrault NA. The dawn of a new era: Transforming our domestic response to hepatitis B&C. Activity 2: Understanding the natural history of HBV and HCV infections. Journal of Family Practice 2010;59(4 Suppl):S16‐S22. - PMC - PubMed
Tong 2010
    1. Tong MJ, Sun HE, Hsien C, Lu DSK. Surveillance for hepatocellular carcinoma improves survival in Asian‐American patients with hepatitis B: Results from a community based clinic. Digestive Diseases and Sciences 2010;55:826‐35. - PubMed
Tsai 2010
    1. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309‐24. - PMC - PubMed
Walter 2011
    1. Walter SR, Thie HH, Amin J, Gidding HF, Ward K, Law MG, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992‐2006. Journal of Hepatology 2011;54(5):879‐86. [DOI: 10.1016/j.jhep.2010.08.035] - DOI - PubMed
WHO 2002
    1. WHO. Hepatitis B. http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf 2002 (accessed 5 July 2012).
Wong 2009
    1. Wong CR, Garcia RT, Trinh HN, Lam KD, Ha NB, Nguyen HA, et al. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Digestive Diseases and Sciences 2009;54:2712‐21. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed
Wun 2000
    1. Wun YT, Dickinson JA. Alpha‐foetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002799] - DOI - PubMed
Yang 2010
    1. Yang HI, Sherman M, Su J, Sen PJ, Law YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Journal of Clinical Oncology 2010;28:2437‐44. - PubMed
Yeung 2005
    1. Yeung YK, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated non‐surgical hepatocellular carcinoma. American Journal of Gastroenterology 2005;100:1995‐2004. - PubMed

References to other published versions of this review

Wun 2003
    1. Wun YT, Dickinson JA. Alpha‐fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD002799] - DOI - PubMed

MeSH terms